Product Description
Mechanisms of Action: MPO Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - Multiple System Atrophy *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Amyotrophic Lateral Sclerosis|Shy-Drager Syndrome|Multiple System Atrophy
Phase 2: Parkinson's Disease|Multiple System Atrophy|Shy-Drager Syndrome
Phase 1: Healthy Volunteers|Parkinson's Disease|Hypotension, Orthostatic|Shy-Drager Syndrome|Multiple System Atrophy|Frontotemporal Dementia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05086094 |
BHV3241-401 | N/A |
No longer available |
Multiple System Atrophy|Shy-Drager Syndrome |
None |
2021-10-21 |
Primary Endpoints|Treatments |
|
NCT05184569 |
Veri-T-001 | P1 |
Active, not recruiting |
Frontotemporal Dementia |
2027-01-31 |
2026-07-07 |
||
NCT04616456 |
2020P003415 | P1 |
Completed |
Hypotension, Orthostatic|Multiple System Atrophy|Shy-Drager Syndrome |
2022-01-30 |
2022-08-20 |
Primary Endpoints |
|
NCT01457807 |
D0490C00003 | P1 |
Completed |
Parkinson's Disease |
2011-12-01 |
2019-03-19 |
Treatments |
|
NCT00914303 |
D0490C00002 | P1 |
Completed |
Healthy Volunteers |
2010-03-01 |
2019-03-18 |
Treatments |
|
NCT00729443 |
SAD | P1 |
Completed |
Healthy Volunteers |
2008-11-01 |
2019-03-18 |
Treatments |
|
2014-004902-13 |
2014-004902-13 | P2 |
Completed |
Multiple System Atrophy |
2016-09-29 |
2022-03-13 |
Treatments |
|
NCT02388295 |
D0490C00023 | P2 |
Completed |
Shy-Drager Syndrome|Multiple System Atrophy |
2016-09-19 |
2019-03-20 |
||
NCT01603069 |
D0490C00005 | P2 |
Completed |
Parkinson's Disease |
2013-06-01 |
2019-03-19 |
Treatments |
|
2011-004803-19 |
2011-004803-19 | P2 |
Completed |
Parkinson's Disease |
2013-01-09 |
2022-03-13 |
Treatments |
|
NCT01527695 |
D0490C00004 | P2 |
Completed |
Parkinson's Disease |
2012-12-01 |
2019-03-19 |
||
2009-018157-23 |
2009-018157-23 | P2 |
Terminated |
Multiple System Atrophy |
2010-12-16 |
2022-03-13 |
Treatments |
|
NCT04297683 |
2019P003518 | P3 |
Active, not recruiting |
Amyotrophic Lateral Sclerosis |
2027-07-01 |
2026-07-22 |
Primary Endpoints|Treatments|Trial Status |
|
NCT04436510 |
2019P003518B | P3 |
Completed |
Amyotrophic Lateral Sclerosis |
2022-04-13 |
2023-06-13 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2019-001100-38 |
2019-001100-38 | P3 |
Completed |
Multiple System Atrophy |
2022-02-22 |
2025-05-06 |
Treatments|Trial Status |
|
NCT03952806 |
M-STAR | P3 |
Completed |
Multiple System Atrophy|Shy-Drager Syndrome |
2021-07-29 |
2023-09-30 |
Patient Enrollment|Primary Endpoints|Treatments |